Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Profound Medical PROF

Healthcare  —  Medical Devices
5.76 0.16 2.86% as of 25 Sep
Market cap
$204.6M
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Profound Medical (PROF) Business Profile

Updated before January 2025

Company Overview

Profound Medical Corp. (PROF) is a leading medical technology company specializing in the development and commercialization of innovative therapeutic systems for the treatment of various medical conditions. Founded in 2008 and headquartered in Mississauga, Ontario, Canada, Profound Medical has established itself as a pioneer in the field of minimally invasive therapies. The company is led by a team of experienced professionals, including Arun Menawat, who serves as the Chairman and Chief Executive Officer. Under his leadership, Profound Medical has achieved significant milestones in advancing its proprietary technologies and expanding its global footprint.

Core Business Segments

Profound Medical operates primarily in the medical technology sector, focusing on the development of therapeutic systems that leverage its proprietary platform. The company’s core business segments include:

1. TULSA-PRO® System

The TULSA-PRO® system is a revolutionary technology designed for the treatment of prostate diseases, including prostate cancer. It combines real-time Magnetic Resonance Imaging (MRI) with robotically driven, transurethral ultrasound technology to deliver precise and customizable thermal ablation of prostate tissue. This minimally invasive procedure offers patients a faster recovery time and fewer side effects compared to traditional surgical methods.

2. Sonalleve® System

The Sonalleve® system is another flagship product of Profound Medical. It is a high-intensity focused ultrasound (HIFU) platform used for the treatment of uterine fibroids and palliative pain relief for bone metastases. The system integrates with MRI to provide real-time imaging and precise targeting, ensuring effective and safe treatment outcomes.

3. Customizable Therapeutic Platforms

Profound Medical also offers customizable therapeutic platforms that cater to the specific needs of healthcare providers. These platforms are designed to integrate seamlessly with existing medical imaging systems, enhancing their functionality and enabling advanced therapeutic applications.

Business Model

Profound Medical’s business model is centered around the development, commercialization, and distribution of its proprietary therapeutic systems. The company generates revenue through the sale of its TULSA-PRO® and Sonalleve® systems, as well as through recurring revenue streams from consumables, service contracts, and software upgrades. Profound Medical also collaborates with leading healthcare institutions and research organizations to drive innovation and expand the clinical applications of its technologies. By focusing on minimally invasive therapies, the company aims to address unmet medical needs and improve patient outcomes.

Strategic Direction

Profound Medical is committed to advancing its position as a leader in the medical technology industry. The company’s strategic priorities include:

  • Expanding Market Penetration: Profound Medical aims to increase the adoption of its TULSA-PRO® and Sonalleve® systems in key markets, including North America, Europe, and Asia-Pacific.
  • Driving Innovation: The company continues to invest in research and development to enhance the capabilities of its existing products and explore new therapeutic applications.
  • Sustainability Goals: Profound Medical is dedicated to promoting sustainability by developing energy-efficient technologies and reducing the environmental impact of its operations.
  • Exploring New Product Categories: The company is actively exploring opportunities to expand its product portfolio and enter new therapeutic areas, such as oncology and neurology.

Competitive Landscape

Profound Medical operates in a highly competitive industry, facing competition from both established players and emerging startups. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of therapeutic solutions.
  • Insightec: A company specializing in focused ultrasound technology for non-invasive treatments.
  • Hologic: A leading provider of medical imaging systems and minimally invasive surgical products.
  • EDAP TMS: A company focused on the development of HIFU technologies for the treatment of prostate cancer and other conditions.

Despite the competitive landscape, Profound Medical differentiates itself through its proprietary technologies, strong clinical evidence, and focus on minimally invasive therapies.

Risk Factors

Like any business, Profound Medical faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily reliant on the sales of its TULSA-PRO® and Sonalleve® systems. Any decline in demand for these products could adversely affect its financial performance.
  • Regulatory Challenges: Profound Medical operates in a highly regulated industry, and any delays or challenges in obtaining regulatory approvals could hinder its ability to commercialize new products.
  • Supply Chain Disruptions: The company relies on a global supply chain for the production of its systems. Disruptions in the supply chain, such as those caused by the COVID-19 pandemic, could impact its ability to meet customer demand.
  • Competition: Intense competition from established players and new entrants could limit Profound Medical’s market share and profitability.

Recent Developments

Profound Medical has made significant strides in recent years, including:

  • Regulatory Approvals: The company received FDA clearance for its TULSA-PRO® system, enabling its commercialization in the United States.
  • Clinical Studies: Profound Medical continues to conduct clinical studies to demonstrate the safety and efficacy of its technologies, further strengthening its value proposition.
  • Partnerships: The company has entered into strategic partnerships with leading healthcare institutions to expand the adoption of its systems and drive innovation.
  • Global Expansion: Profound Medical has expanded its presence in key international markets, including Europe and Asia-Pacific, to capitalize on growing demand for minimally invasive therapies.

Investment Considerations

Investors considering Profound Medical as a potential investment should weigh the following strengths and risks:

Strengths

  • Innovative and proprietary technologies with strong clinical evidence.
  • Growing demand for minimally invasive therapies.
  • Recurring revenue streams from consumables and service contracts.
  • Experienced leadership team with a proven track record.

Risks

  • Dependence on a limited number of products for revenue generation.
  • Regulatory and competitive challenges.
  • Potential supply chain disruptions.
  • High research and development costs.

Conclusion

Profound Medical is well-positioned to capitalize on the growing demand for minimally invasive therapies. With its innovative technologies, strong clinical evidence, and strategic focus on market expansion and innovation, the company is poised for long-term growth. However, investors should carefully consider the associated risks before making an investment decision. As Profound Medical continues to advance its mission of improving patient outcomes, it remains a key player in the medical technology industry with significant growth potential.